相关实验视频

Updated: May 5, 2026

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

治疗眼睛和未经治疗的同眼之间可比的胸膜厚度在患有单侧神经血管性AMD的患者中:双眼对比研究

Francesco Cinque¹, Femke M van den Tillaert¹, Suzanne Yzer¹

¹Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen, 6525, The Netherlands.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

|March 8, 2025

概括

针对神经血管与年龄相关的黄斑变性 (AMD) 的抗血管内皮生长因子 (anti-VEGF) 治疗与未经治疗的同眼相比,在治疗的眼睛中没有显著改变胸膜厚度 (CT). 反VEGF注射的数量也与CT的变化没有相关性.

科学领域:

眼科医生眼科眼科
视网膜疾病视网膜疾病
医疗治疗医疗治疗

背景情况:

内抗血管内皮生长因子 (anti-VEGF) 是排泄性新血管与年龄相关的黄斑变性 (AMD) 的主要治疗方法.
在两年内,大约25%接受抗VEGF治疗的新血管AMD患者可能会出现黄斑缩,这可能与治疗有关.

研究的目的:

为了研究抗VEGF治疗对单侧新血管AMD患者的胸腔厚度 (CT) 的影响.
探索长期治疗新血管性AMD患者的抗VEGF注射数量和CT之间的关系.

主要方法:

一项涉及112名患有单边新血管AMD的患者的横截面研究,使用同眼作为对照.
带有增强深度成像 (EDI) 的光谱域光学连贯性断层扫描 (SD-OCT) 用于在五个不同的位置测量CT.
统计分析包括配对的t测试和多重线性回归来评估CT差异和影响因素,包括地理缩 (GA).

主要成果:

在新血管 (NV) 和非新血管 (NNV) 眼睛之间没有观察到 subfoveal choroidal 厚度 (SFCT) 的统计学上显著差异,NV 眼睛的CT 较薄的初始趋势是不显著的.
年龄是SFCT的唯一显著预测因素;抗VEGF注射的数量与CT无关.
与非GA眼相比,同眼中的地理缩 (GA) 存在并没有显著影响SFCT.

结论:

这项研究发现,用抗VEGF治疗的新血管性AMD眼睛与未经治疗的眼睛之间,胸膜厚度没有统计学上显著的差异.
抗VEGF注射的累积数量与胸膜厚度的变化之间没有可证明的关系.
这些发现表明,通过抗VEGF注射的次要冠状腺稀释诱导缩可能在长期新血管AMD管理中具有有限的临床关注.

关键词:

与年龄相关的黄斑变性.抗-VEGFF是一种抗生素.化物化物化物马库拉 (Macula) 是一个斑点.

更多相关视频

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...